Regulus Therapeutics Inc.
RGLS
$3.51
$0.020.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 62.12% | 227.33% | 66.98% | 22.64% | 335.26% |
| Gross Profit | -62.12% | -227.33% | -66.98% | -22.64% | -335.26% |
| SG&A Expenses | 60.58% | 46.49% | 68.92% | 13.99% | 14.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.61% | 87.20% | 67.60% | 19.77% | 19.73% |
| Operating Income | -65.61% | -87.20% | -67.60% | -19.77% | -19.73% |
| Income Before Tax | -58.68% | -79.73% | -57.37% | -18.63% | -18.63% |
| Income Tax Expenses | -- | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | -58.68% | -79.73% | -57.36% | -18.63% | -18.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.68% | -79.73% | -57.36% | -18.63% | -18.63% |
| EBIT | -65.61% | -87.20% | -67.60% | -19.77% | -19.73% |
| EBITDA | -66.09% | -87.38% | -67.46% | -19.45% | -19.21% |
| EPS Basic | 51.00% | 46.11% | 53.36% | 30.49% | 1.21% |
| Normalized Basic EPS | 50.98% | 46.13% | 53.36% | 30.50% | 1.23% |
| EPS Diluted | 51.00% | 46.11% | 53.36% | 30.49% | 2.09% |
| Normalized Diluted EPS | 50.98% | 46.13% | 53.36% | 30.50% | 1.23% |
| Average Basic Shares Outstanding | 223.90% | 233.55% | 237.48% | 70.66% | 20.09% |
| Average Diluted Shares Outstanding | 223.90% | 233.55% | 237.48% | 70.66% | 20.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |